News | June 02, 2009

Endoscopic Radiofrequency Ablation Safe in Community Practice Setting

June 2, 2009 - Clinical trial results presented at the Digestive Disease Week in Chicago today reveal that endoscopic radiofrequency ablation performed in a community practice setting is safe and effective for eradicating a pre-cancerous esophageal condition known as Barrett's esophagus.

The study, "Radiofrequency Ablation of Barrett Esophagus: Outcomes of 429 Patients from a Multicenter Community Practice Registry," was presented on June 1, 2009, by Ronald E. Pruitt, M.D., Nashville, Tenn., at a scientific session sponsored by the American Society of Gastrointestinal Endoscopy.

The study's author reported on 429 patients with Barrett's esophagus, with and without advanced dysplasia (cellular signs of advanced progression towards cancer), who were treated with radiofrequency ablation using the HALO ablation system (BARRX Medical, Sunnyvale, Calif.) over the last four years. They report that the adverse event rate was favorable, with a low stricture risk (about 1 percent) and no serious adverse events. After an average of two ablation procedures and 20 month follow-up, 77 percent of patients were cured of their Barrett's disease. For those patients that had baseline evidence of dysplasia, 100 percent had complete eradication of all signs of dysplasia.

"We believe that the results of our trial are unique and relevant to the scientific knowledge-base, as this is the largest patient experience reported to date and the first multi-center trial conducted at community practice centers for using radiofrequency ablation to eradicate Barrett's esophagus," said Dr. Pruitt. "Most importantly, we found that the safety and efficacy outcomes garnered in this clinical setting comport with those from reported trials conducted as predominantly academic tertiary referral centers."

Study centers were comprised of large community practices with expertise in therapeutic endoscopy and the management of Barrett's esophagus. Radiofrequency ablation was applied with a balloon-based circumferential device and an endoscope mounted focal device. Patients underwent biopsy sampling of tissue from the esophagus at regular intervals to determine if all Barrett's disease had been eradicated. To be considered a "complete responder," all biopsy samples had to be normal.

For more information: www.barrx.com

Related Content

Hologic Receives CE Mark for Three-in-One Omni Hysteroscope
News | Endoscopes | March 14, 2019
Hologic Inc. announced it has received a CE mark in Europe for its Omni hysteroscope, a three-in-one modular scope with...
Videos | Advanced Visualization | March 05, 2019
This is an example of a new endoscopic virtual peritoneal inflation tool on the patient's computed tomography (CT) im
Videos | Advanced Visualization | March 05, 2019
This is an example of a new endoscopic 3-D imaging simulator created from a patient's computed tomography (CT) scan u
Fujifilm Launches Latest Synapse 3D Version at HIMSS 2019

The new Intravoxel Incoherent Motion (IVIM) MR application in Synapse 3D

Technology | Advanced Visualization | February 08, 2019
Fujifilm Medical Systems U.S.A. will debut the latest version of its Synapse 3D solution at the Healthcare Information...
Body Vision Medical Announces Release of LungVision
Technology | Lung Cancer | October 05, 2018
Body Vision Medical, a medical device company specializing in lung cancer diagnostics, announced the launch of its...
American Society for Gastrointestinal Endoscopy and Touch Surgery Pilot Video-Based Endoscopic Simulations
News | Endoscopes | June 11, 2018
During the 2018 Digestive Disease Week (DDW) conference June 2-5 in Washington, D.C., the American Society for...
Olympus and Hitachi Healthcare Americas Introduce Arietta 850
News | Ultrasound Imaging | June 04, 2018
Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedu
Body Vision Medical Receives FDA Clearance for LungVision Tool
Technology | Lung Cancer | May 09, 2018
Body Vision Medical received clearance from the U.S. Food and Drug Administration (FDA) to market their LungVision Tool...
El Camino Hospital Performs First U.S. Robotic Lung Cancer Bronchoscopy
News | Oncology Diagnostics | April 25, 2018
The interventional pulmonology team at the Taft Center for Clinical Research at El Camino Hospital in Mountain View,...
News | Endoscopes | April 02, 2018
Results from a recent prospective trial found the Wide Area Transepithelial Sampling with 3D Tissue Analysis (WATS3D)...